Elevation Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, and US Oncology Research, one of the largest community-based oncology site management organizations in the U.S., announced a collaboration to utilize the US Oncology Research Selected Trials for Accelerated Rollout (STAR) program for patient enrollment in the registration-enabling Phase 2 CRESTONE study for patients with solid tumors of any origin that have an NRG1 gene fusion.
“The ability to accurately detect rare genomic driver alterations in a patient’s tumor and subsequently open up a clinical study site in response, is paramount to bringing precision therapy opportunities to patients that may benefit from treatment,” said Shawn Leland, founder and chief business officer of Elevation Oncology. “US Oncology Research is ideally positioned to expand the reach of the CRESTONE study for patients with cancers harboring an NRG1 gene fusion for investigational treatment with seribantumab. A key component of this collaboration is the ability to quickly open CRESTONE clinical trial sites via the US Oncology Research STAR program, which minimizes patient travel and disruption in clinical care, a major advantage particularly given the current travel complexities due to COVID-19.”
The STAR program opens and activates clinical trials quickly across all cancer research sites managed by US Oncology Research. STAR is an operational model that allows for pre-screening of potentially eligible subjects upfront and only opens sites where subjects are identified. When a potential STAR trial patient is identified at a facility, the practice is trained in the details of the trial, and the study is opened within a two-week timeframe at the location where the patient will be treated.
US Oncology Research serves approximately 60 research sites and more than 165 locations, managing about 400 active trials at any given time.
Patients and physicians can learn more about the CRESTONE study at www.nrg1fusion.com or on www.ClinicalTrials.gov under the NCT number NCT04383210.
